Molecules

DCFPyL

Target PSMAClass Small molecule (urea, fluoropyridine)Other names piflufolastat

22ongoing trials
1radiolabelled forms
1approved products
484publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C18H23FN4O8
Molar mass (g/mol)
442.4
Exact mass (Da)
442.15
XLogP
-0.1
H-bond donors
6
H-bond acceptors
10
Rotatable bonds
13
Heavy atoms
31
InChIKey
OLWVRJUNLXQDSP-RYUDHWBXSA-N
PubChem record
CID 71532123 ↗
IUPAC name
(2S)-2-[[(1S)-1-carboxy-5-[(6-fluoropyridine-3-carbonyl)amino]pentyl]carbamoylamino]pentanedioic acid
SMILES
C1=CC(=NC=C1C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O)F

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁸F]DCFPyL Syntheses and QC ↗Imaging441.422Phase 3Pylarify / Pylclari US EU FR

Ongoing trials · 22Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
[68Ga]Ga-PSMA-112024-518171-59-00 · Prostate – otherPhase 3RecruitingCanisius Wilhelmina Ziekenhuis1
[18F]DCFPyL (piflufolastat)NCT03594760 · Prostate – otherPhase 3RecruitingCentre hospitalier de l'Université de Montréal (CHUM)1
[18F]DCFPyL (piflufolastat)NCT03824275 · Prostate – otherPhase 3Active, not recruitingColumbia University1
[18F]DCFPyL (piflufolastat)NCT03459820 · Prostate – otherPhase 3By invitationSir Mortimer B. Davis - Jewish General Hospital1
[18F]DCFPyL (piflufolastat)NCT03495427 · Prostate – otherPhase 3RecruitingH. Lee Moffitt Cancer Center and Research Institute1
[18F]DCFPyL (piflufolastat)NCT03173924 · Prostate – otherPhase 2Active, not recruitingNational Cancer Institute (NCI)1
[18F]DCFPyL (piflufolastat)NCT03471650 · Prostate – otherPhase 2Active, not recruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
[68Ga]Ga-PSMA-11NCT03181867 · Prostate – localised / recurrencePhase 2Active, not recruitingNational Cancer Institute (NCI)1
[18F]DCFPyL (piflufolastat)NCT03976843 · Prostate – localised / recurrencePhase 2Active, not recruitingNational Cancer Institute (NCI)1
[18F]DCFPyL (piflufolastat)NCT06904313 · Prostate – otherPhase 2RecruitingAkiva Mintz1
[18F]DCFPyL (piflufolastat)NCT07635524 · Prostate – otherPhase 2Not yet recruitingHoag Memorial Hospital Presbyterian1
[18F]DCFPyL (piflufolastat)NCT04700332 · Prostate – localised / recurrencePhase 2RecruitingHoag Memorial Hospital Presbyterian1
[18F]DCFPyL (piflufolastat)2026-525181-22-00 · Prostate – otherPhase 1Not yet recruitingCentre Hospitalier Universitaire De Toulouse1
[18F]DCFPyL (piflufolastat)NCT06586047 · BreastPhase 1RecruitingAhmad Shariftabrizi1
[18F]DCFPyL (piflufolastat)NCT05394259 · BreastPhase 1Active, not recruitingM.D. Anderson Cancer Center1
[18F]DCFPyL (piflufolastat)NCT06756334 · Prostate – localised / recurrencePhase 1RecruitingAnhui Provincial Hospital1
[18F]DCFPyL (piflufolastat)NCT03392181 · Prostate – otherPhase 1Active, not recruitingNorthwestern University1
MIRROR · [18F]DCFPyL (piflufolastat)NCT06074510 · Prostate – otherNo phaseActive, not recruitingLantheus Medical Imaging1
[18F]DCFPyL (piflufolastat)NCT05919329 · Prostate – mCRPCNo phaseRecruitingOHSU Knight Cancer Institute1
TAYLOR · Other PSMA ligandNCT06917781 · Prostate – otherNo phaseRecruitingInstitut Claudius Regaud1
[18F]DCFPyL (piflufolastat)NCT05470699 · Prostate – otherNo phaseActive, not recruitingCity of Hope Medical Center1
[18F]DCFPyL (piflufolastat)NCT06099093 · Prostate – mCRPCNo phaseRecruitingBrigham and Women's Hospital1
Other trials listing it among the interventions (comparator, associated scan) · 1
[18F]FDGNCT06335914 · Prostate – otherNo phaseRecruitingUniversity Health Network, Toronto1

Published results · 1

2026-06Fluciclovine contre DCFPyL · positiveIn 50 patients with biochemical recurrence at low PSA (0.2 to 2 ng/mL) after robotic prostatectomy, DCFPyL is positive in 44% of cases vs 24% for fluciclovine, with a clear advantage for pelvic lymph nodes (22% vs 8%).Eur J Nucl Med Mol Imaging ↗

PublicationsAll publications in PubMed ↗

484 publications in PubMed for the query below; the most recent:

DCFPyL[tiab] OR piflufolastat[tiab]

  1. Solitary urothelial carcinoma penile metastasis on (18)F-FDG PET/CT Radiol Case Rep, 2026
  2. Incidental Glioblastoma Multiforme Detected on 18 F-DCFPyL PET/CT Prostate Cancer Staging Clin Nucl Med, 2026
  3. 18 F-fluciclovine PET Imaging of Non-PSMA Expressing High-risk Primary Prostate Cancer Clin Nucl Med, 2026
  4. Effect of data-driven gating on the quantification of prostate cancer metastases in (68)Ga-PSMA- and ¹⁸F-DCFPyL-PSMA PET/CT EJNMMI Rep, 2026
  5. Comparative analysis of treatment response to PSMA radioligand therapy using Ga-68 PSMA-11 and F-18 DCFPyL PET imaging Front Oncol, 2026
  6. PSMA-avid Pleural Solitary Fibrous Tumor Incidentally Detected on [ 18 F] Piflufolastat PSMA PET/CT Clin Nucl Med, 2026
  7. Comparison of [(18)F]DCFPyL and [(18)F]FAPI-74 PET/CT imaging in metastatic prostate cancer Eur J Nucl Med Mol Imaging, 2026
  8. Limited incremental prognostic value of pretreatment MRI and (18)F-piflufolastat PET intensity metrics in grade group ≥ 3 prostate cancer Abdom Radiol (NY), 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

DCFPyL. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/dcfpyl/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.